2,同時(shí)第1天也靜脈推注注射用環(huán)磷酰胺,600 mg/m2,14 d為1個(gè)周期,治療4個(gè)周期;之后序貫第1天靜脈滴注注射用紫杉醇(白蛋白結(jié)合型),175 mg/m2,14 d為1個(gè)周期,治療4個(gè)周期。治療組在對(duì)照組治療的基礎(chǔ)上靜脈注射注射用香菇多糖,1 mg用2 mL注射用水振搖溶解,加入到生理鹽水250 mL中,2次/周,14 d為1個(gè)周期,治療4個(gè)周期后進(jìn)行觀察。觀察兩組的近期臨床療效,比較兩組的生活質(zhì)量評(píng)分、淋巴細(xì)胞亞群水平、不良反應(yīng)情況。結(jié)果 治療后,對(duì)照組和治療組的客觀有效率(ORR)分別為56.7%、63.3%,疾病控制率(DCR)分別為86.7%、90.0%,兩組比較差異無有統(tǒng)計(jì)學(xué)意義。治療后,兩組患者KPS評(píng)分升高,同組治療前后比較差異無統(tǒng)計(jì)學(xué)意義,且兩組治療后比較差異亦無統(tǒng)計(jì)學(xué)意義。治療后,對(duì)照組患者CD4+/CD8+水平顯著降低,治療組患者CD4+、CD4+/CD8+水平均顯著升高,同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療后治療組CD4+、CD4+/CD8+水平明顯高于對(duì)照組,兩組治療后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組白細(xì)胞降低、惡心嘔吐的Ⅲ~Ⅳ發(fā)生率均明顯低于對(duì)照組,兩組不良反應(yīng)發(fā)生率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 注射用香菇多糖聯(lián)合AC方案和紫杉醇治療晚期三陰性乳腺癌具有較好的臨床療效,能改善患者淋巴細(xì)胞亞群水平,降低不良反應(yīng),具有一定的臨床推廣應(yīng)用價(jià)值。;Objective To evaluate the efficacy and safety of Lentinan for injection combined with AC regimen and paclitaxel in treatment of advanced triple negative breast cancer. Methods Patients (60 cases) with advanced triple negative breast cancer in the First Teaching Hospital of Tianjin University of TCM and Tianjin Medical University Cancer Institute & Hospital from January 1st 2015 to December 1st 2017 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were given AC regimen:the first day, patients were iv administered with Doxorubicin Hydrochloride for injection, 60 mg/m2, and the first day, patients were also iv administered with Cyclophosphamide for injection, 600 mg/m2, 14 d for 1 cycle, treated for 4 cycles. After this, sequential therapy, the first day, patients were iv administered with Paclitaxel for injection (Albumin Bound), 175 mg/m2, 14 d for 1 cycle, treated for 4 cycles. Patients in the treatment group were iv administered with Lentinan for injection on the basis of the control group, 1 mg was dissolved by shaking with 2 mL water for injection and added into 250 mL normal saline, twice weekly, 14 d for 1 cycle, and treated for 4 cycles. After treatment, the short-term clinical efficacies were evaluated, and quality of life score, the levels of lymphocyte subsets, and adverse reactions in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 56.7% and 63.3%, respectively, and the DCR in the control and treatment groups were 86.7% and 90.0%, respectively, and there was no difference between two groups. After treatment, KPS scores in two groups were decreased, and the difference was no statistically significant in the same group, and there no significant difference between two groups. After treatment, CD4+/CD8+ in the control group were significantly decreased, CD4+, CD4+/CD8+ in the treatment group were significantly increased (P<0.05). And the levels of lymphocyte subsets in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the incidence of Ⅲ-Ⅳ of leucopenia, nausea and vomiting in the treatment group were significantly lower than those in the control group, and there was difference between two groups (P<0.05). Conclusion Lentinan for injection combined with AC regimen and paclitaxel has clinical curative effect in treatment of advanced triple negative breast cancer, can improve the level of lymphocyte subsets, and reduce adverse reactions, which has a certain clinical application value."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2020年第35卷第1期 >2020,35(1):26-31. DOI:10.7501/j.issn.1674-5515.2020.01.006
上一篇 | 下一篇

注射用香菇多糖聯(lián)合AC方案和紫杉醇治療晚期三陰性乳腺癌的臨床研究

Clinical study on Lentinan for injection combined with AC regimen and paclitaxel in treatment of advanced triple negative breast cancer

發(fā)布日期:2020-03-06